Unknown

Dataset Information

0

TGF-? signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts.


ABSTRACT: Activation of TGF-? signaling is known to promote epithelial-mesenchymal transition (EMT) for the development of metastatic castration-resistant prostate cancer (mCRPC). To determine whether targeting TGF-? signaling alone is sufficient to mitigate mCRPC, we used the CRISPR/Cas9 genome-editing approach to generate a dominant-negative mutation of the cognate receptor TGFBRII that attenuated TGF-? signaling in mCRPC cells. As a result, the delicate balance of oncogenic homeostasis is perturbed, profoundly uncoupling proliferative and metastatic potential of TGFBRII-edited tumor xenografts. This signaling disturbance triggered feedback rewiring by enhancing ERK signaling known to promote EMT-driven metastasis. Circulating tumor cells displaying upregulated EMT genes had elevated biophysical deformity and an increase in interactions with chaperone macrophages for facilitating metastatic extravasation. Treatment with an ERK inhibitor resulted in decreased aggressive features of CRPC cells in vitro. Therefore, combined targeting of TGF-? and its backup partner ERK represents an attractive strategy for treating mCRPC patients.

SUBMITTER: Huang G 

PROVIDER: S-EPMC5363574 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts.

Huang Guangcun G   Osmulski Pawel A PA   Bouamar Hakim H   Mahalingam Devalingam D   Lin Chun-Lin CL   Liss Michael A MA   Kumar Addanki Pratap AP   Chen Chun-Liang CL   Thompson Ian M IM   Sun Lu-Zhe LZ   Gaczynska Maria E ME   Huang Tim H-M TH  

Oncotarget 20161101 47


Activation of TGF-β signaling is known to promote epithelial-mesenchymal transition (EMT) for the development of metastatic castration-resistant prostate cancer (mCRPC). To determine whether targeting TGF-β signaling alone is sufficient to mitigate mCRPC, we used the CRISPR/Cas9 genome-editing approach to generate a dominant-negative mutation of the cognate receptor TGFBRII that attenuated TGF-β signaling in mCRPC cells. As a result, the delicate balance of oncogenic homeostasis is perturbed, pr  ...[more]

Similar Datasets

| S-EPMC3887298 | biostudies-literature
| S-EPMC4437893 | biostudies-literature
| S-EPMC5438896 | biostudies-literature
| S-EPMC6014098 | biostudies-literature
| S-EPMC6600375 | biostudies-literature
| S-EPMC4034764 | biostudies-literature
| S-EPMC3075272 | biostudies-literature
| S-EPMC7385392 | biostudies-literature
| S-EPMC4018787 | biostudies-literature
| S-EPMC3391666 | biostudies-literature